Lurbinectedin is a chemotherapy drug that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic small cell lung cancer (SCLC) in patients who have previously received chemotherapy. According to the sources provided, there is no information suggesting that lurbinectedin can be used with all therapies.

Lurbinectedin is a type of chemotherapy drug that works by blocking the activity of a protein called RNA polymerase II, which is essential for the growth and survival of cancer cells. It has been shown to be effective in treating metastatic SCLC, a type of lung cancer that is known for its aggressive nature and poor prognosis [3].

Zepzelca is the brand name for lurbinectedin, and it is currently the only FDA-approved treatment for metastatic SCLC that has progressed after previous treatment with chemotherapy. However, there is no information available on whether lurbinectedin can be used in combination with other therapies for SCLC or other types of cancer [2].

The drug patent watch website provides information on the patent status of lurbinectedin, but it does not provide any information on the use of the drug with other therapies [1].

A study published in the Journal of Clinical Oncology evaluated the efficacy and safety of lurbinectedin in combination with doxorubicin, another chemotherapy drug, in patients with advanced solid tumors. The study found that the combination therapy was well-tolerated and had promising anti-tumor activity, but further studies are needed to determine the optimal dose and schedule for this combination therapy [3].

In conclusion, while lurbinectedin has been approved for the treatment of metastatic SCLC, there is no information suggesting that it can be used with all therapies. Further studies are needed to determine the safety and efficacy of lurbinectedin in combination with other therapies for SCLC or other types of cancer.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.zepzelca.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331752/